Rosuvastatin
High-potency statin without CYP3A4 metabolism for lipid management
Rosuvastatin is a synthetic, fully competitive HMG-CoA reductase inhibitor belonging to the statin drug class. Approved in 2003 and marketed under the trade name Crestor, it is one of the most potent statins available and can achieve LDL reductions of 45 to 63 percent across its dose range. Rosuvastatin is distinguished from atorvastatin and simvastatin by its lack of significant CYP3A4 metabolism, reducing the number of clinically relevant drug interactions.
Rosuvastatin is now widely available as a generic drug. The JUPITER trial provided evidence that rosuvastatin reduces cardiovascular events in patients with normal LDL but elevated high-sensitivity CRP, broadening the potential population for statin therapy. It is a preferred statin in many international guidelines for patients requiring high-intensity lipid lowering.
Mechanism of Action
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis, more potently than most other statins per milligram of drug. Inhibition of this pathway reduces intracellular cholesterol synthesis in hepatocytes, upregulates LDL receptors on the hepatocyte surface, and increases LDL clearance from the circulation.
Unlike atorvastatin, simvastatin, and lovastatin, rosuvastatin is not appreciably metabolised by CYP3A4. It is primarily eliminated via CYP2C9 and directly excreted, and it is a substrate of hepatic uptake transporters OATP1B1 and OATP1B3. This metabolic profile reduces interactions with CYP3A4 inhibitors but means that inhibitors of OATP transporters (such as ciclosporin) can significantly increase rosuvastatin exposure.
Rosuvastatin also has pleiotropic effects comparable to atorvastatin: anti-inflammatory effects, improvement of endothelial function, reduction of CRP, and plaque stabilisation.
Indications
- Primary hypercholesterolaemia and mixed dyslipidaemia: Adjunct to diet for reduction of elevated total cholesterol, LDL-C, apolipoprotein B, and triglycerides
- Homozygous familial hypercholesterolaemia: In combination with other lipid-lowering therapies or when other treatments are not appropriate
- Cardiovascular prevention: High-intensity statin therapy in very high-risk patients (post-ACS, diabetes with target organ damage, familial hypercholesterolaemia)
- Elevated hsCRP with low LDL (JUPITER indication): Primary prevention in patients with LDL below 3.4 mmol/l but hsCRP above 2 mg/l
Dosage and Administration
Starting dose: 5 to 10 mg once daily. Titration: 20 mg once daily after 4 weeks if target not achieved; maximum 40 mg once daily. High-intensity therapy: 20 to 40 mg for very high-risk patients requiring greater than 50 percent LDL reduction.
Rosuvastatin can be taken at any time of day, with or without food. Unlike simvastatin, evening dosing is not required. Dose reduction to 5 mg is recommended for Asian patients (East Asian ethnicity) as rosuvastatin plasma levels are approximately twice as high in this population. Severe renal impairment (CrCl below 30 ml/min) limits the maximum dose to 20 mg; severe hepatic impairment contraindicates use.
Side Effects
Common (1 to 10 percent): Headache, myalgia, abdominal pain, nausea, constipation, weakness. The frequency of myalgia is similar to other statins at equivalent LDL-lowering doses.
Rare but serious: Myopathy and rhabdomyolysis — the risk is dose-dependent and substantially increased in combination with drugs that raise rosuvastatin plasma levels. Proteinuria and haematuria (notably more common with rosuvastatin than other statins at high doses, particularly 40 mg — monitor urine protein at baseline and during therapy at high doses). Hepatic dysfunction. New-onset diabetes mellitus (class effect of all statins).
At 40 mg dose: The highest approved dose of 40 mg should be used only when the 20 mg dose has not achieved the treatment goal and when high-risk patients are unlikely to benefit from a switch to an alternative statin. Renal and hepatic monitoring is more important at this dose.
Interactions
- Ciclosporin: Markedly increases rosuvastatin AUC (approximately 7-fold); combination results in maximum dose of 5 mg daily
- Gemfibrozil: Increases rosuvastatin exposure by approximately 2-fold; combination should be avoided or dose limited to 10 mg
- HIV antiretrovirals (lopinavir/ritonavir, atazanavir/ritonavir): Significant increases in rosuvastatin exposure; careful dose limitation required
- Antacids containing aluminium and magnesium: Reduce rosuvastatin absorption by approximately 50 percent; administer rosuvastatin at least 2 hours before antacids
- Fusidic acid: Increased risk of myopathy; rosuvastatin should be temporarily discontinued during systemic fusidic acid courses
- Warfarin: Rosuvastatin may increase INR; monitor anticoagulation when initiating or adjusting rosuvastatin therapy
Special Notes
Asian patients: Pharmacokinetic studies show approximately 2-fold higher plasma levels in East Asian patients compared with Caucasians. The starting dose should be 5 mg and the maximum dose 20 mg in this population to reduce the risk of myopathy.
Proteinuria monitoring: Dipstick proteinuria has been observed more frequently with rosuvastatin, particularly at 40 mg. Baseline and periodic urine protein monitoring is recommended at the highest dose. This effect appears to be a tubular rather than glomerular process and does not indicate progressive renal damage in most cases.
Pregnancy and breastfeeding: Rosuvastatin is absolutely contraindicated in pregnancy and breastfeeding. Statins inhibit cholesterol biosynthesis, which is essential for foetal and neonatal development.
Related Topics
- Atorvastatin — Most widely used high-potency statin
- Ezetimibe — Cholesterol absorption inhibitor, often combined with statins
- All active ingredients overview
Frequently Asked Questions
Is rosuvastatin better than atorvastatin?
At equivalent doses, rosuvastatin typically lowers LDL cholesterol by about 10 to 15 percent more than atorvastatin. However, both are high-intensity statins and the clinical outcome benefit appears broadly comparable in head-to-head data. The choice often depends on tolerability, interaction profile, and individual patient factors. Rosuvastatin's lack of CYP3A4 metabolism may be advantageous in patients on interacting medications.
Why must Asian patients take a lower dose of rosuvastatin?
Pharmacokinetic studies have consistently shown that East Asian patients have approximately twice the plasma concentration of rosuvastatin for a given dose compared with Caucasian patients. The reason is thought to relate to differences in OATP1B1 transporter activity. Lower starting doses reduce the risk of myopathy without significantly compromising lipid-lowering efficacy.
Does rosuvastatin need to be taken in the evening?
No. Unlike simvastatin and lovastatin, which have short half-lives and are most effective when taken in the evening to coincide with peak nocturnal cholesterol synthesis, rosuvastatin has a half-life of approximately 19 hours. It can be taken at any time of day; what matters most is daily consistency.